Severe Hunter syndrome is a fatal X-linked lysosomal storage disorder caused by iduronate-2-sulphatase (IDS) deficiency. Patients with complete deletion of the IDS locus often have atypical phenotypes including ptosis, obstructive sleep apnoea, and the occurrence of seizures. We have used genomic DNA sequencing to identify several new genes in the IDS region. DNA deletion patients with atypical symptoms have been analysed to determine whether these atypical symptoms could be due to involvement of these other loci. The occurrence of seizures in two individuals correlated with a deletion extending proximal of IDS, up to and including part of the FMR2 locus. Other (non-seizure) symptoms were associated with distal deletions. In addition, a group of patients with no variant symptoms, and a characteristic rearrangement involving a recombination between the IDS gene and an adjacent IDS pseudogene (IDSv|/), showed normal expression of loci distal to IDS. Together, these results identify FMR2 as a candidate gene for seizures, when mutated along with IDS.
INTRODUCTION
Deficiency of the enzyme iduronate-2-sulphatase (IDS, EC3.1.6.13) results in Hunter syndrome (mucopolysaccharidosis type II, MPS-II), an X-linked recessive disorder. In the severe form of this disease abnormal storage of dermatan and heparan sulphate results in progressive mental retardation, physical disability and death before age 15 (1) . The incidence of Hunter syndrome is ~1 in 132 000 live male births (2) . The majority of cases are caused by point mutations and small deletions or insertions, with -20% of cases being the result of major structural alterations, including large deletions and rearrangements (3) . In between 6 and 8% (4) (5) (6) (7) (8) of cases the disease is the result of complete deletion of the IDS gene. Patients with complete deletion of IDS have been described with additional symptoms not commonly associated with Hunter syndrome, including the occurrence of seizures (4, 9) . These variant phenotypes may be due to involvement of loci adjacent to the IDS gene (4, 9) .
In -13% of patients with Hunter syndrome there has been an homologous recombination event between the IDS gene and an adjacent unexpressed IDS pseudogene (IDSv|/), resulting in a disruption of the IDS gene in intron 7 and an inversion of the intervening DNA (10) . These individuals have the severe MPS-II phenotype, with no variant symptoms. IDS gene transcripts in these patients contain novel sequences at their 3' end (11) , suggesting that neighbouring loci may also be affected by the lesion in these individuals.
Two groups of patients with severe Hunter syndrome, with and without atypical symptoms, were analysed to determine whether the mutations in these individuals involved genes located in close proximity to the IDS gene. Mapping of deletion breakpoints demonstrated a correlation between the observed genotype and the atypical symptoms found in these patients. In individuals where the causative mutation was homologous recombination between IDS and IDS\|/, the mutation had no major effect on expression of other loci in this region. These phenotype-genotype correlations define a critical region and candidate gene for the seizures observed in some individuals with deletion of the IDS locus.
RESULTS

Genomic DNA sequence of the IDS region
Sequencing of the IDS region has revealed that its organisation is very complex and that it is gene-rich (Fig. 1) . Analysis of a 206 kb sequence contig (GenBank accession no. U66082) from the IDS region identified three genes (X, W and Y) in addition to IDS and IDS\|/. Sequence from a second 73 kb contig (GenBank accession no. U66083) revealed that 27.5 kb of contiguous sequence, including all three newly identified genes, have been locally duplicated on Xq28. RT-PCR, cDNA isolation and sequencing, and computer analysis (33, 35) were used to characterise these previously unknown genes. No similarity was found with known genes in the computer databases, and no potential functional roles have been assigned. Several factors including detectable levels of expression, tissue specific express- ion in the case of gene W (data not shown), and expression of both copies of duplicated genes would suggest that all these genes are functional.
Deletions in patients with seizures extend proximal of IDS
Four patients with deletions spanning the IDS gene were analysed. PCRs or Southern hybridisations were carried out using STS markers and genes mapped from the boundary of Xq27.3-28. Earlier mapping studies carried out with these patients also gave some information on markers located proximal of and/or distal to our sequence contigs (7, 12, 13) . All four of the patients were found to have deletions spanning IDS, IDSy, W and X. These data are summarised in Figure 2 . Patient 1 has severe MPS-II and additional Hurler-like (MPS-I) symptoms (8) . In this individual the proximal deletion breakpoint is located between IDS and the marker DXS1J23. Analysis of sequence from this region has failed to identify any genes between DXS1123 and IDS. Distal of IDS, the deletion includes all seven genes we have identified. As the distance between IDS and gene Z' is thought to be between 0.5 and 1 Mb it is likely that additional unidentified coding sequences present between the two sequence contigs are also deleted in this individual.
In the two patients (patients 2 and 3 in Fig. 2 ) who suffer from seizures in addition to the severe MPS-II phenotype, the deletions extended proximal of IDS towards FRAXE. FRAXE is a recently identified folate sensitive fragile site (14) , and expansion of the (CCG) n repeat at FRAXE is associated with mild mental retardation (15) (16) (17) . Recent reports (18, 19) have identified a gene (FMR2) located distal of FRAXE. Expansion of the FRAXE (CCG)n repeat results in decreased expression of this gene (18, 19) . It is possible that unidentified loci located between FRAXE and IDS are also deleted in these two individuals. It is also likely that the FMR2 locus is partially deleted, as recent studies indicate that markers DXS296 and DXS295 are located within the FMR2 gene (18, 19) . DXS296 overlaps exon 3 of FMR2 and has been used as a probe to isolate FMR2 cDNAs (19) . Southern hybridisations indicated that DXS295 is located in FMR2 at the 3' end of the gene. However, subsequent PCR experiments suggest that this marker may be located distal to the 3' end of FMR2 (Jozef Gecz, personal communication). The distal deletion breakpoint in one of these patients (patient 3) has been mapped to within 6 kb, and is located between genes Y' and X' in the distal sequence contig. PCR with gene Y/Y' primers on DNA from patient 2 yielded a positive result. These genes have >90% identical sequence and are indistinguishable by PCR or hybridisation. Therefore, one or both of these genes is present in this individual.
Patient 4 has ptosis in addition to severe Hunter syndrome (9) . The deletion in this individual is less extensive than the other three. The proximal breakpoint is between markers DXS295 and DXS1123, i.e. proximal of patient 1, but distal of patients 2 and 3. At the distal end of the deletion this patient shows the same pattern as patient 2, however extensive further mapping is required to localise the distal breakpoints in these two individuals.
In summary, in two IDS patients with seizures there are deletions that extend much further proximal than in the patients without seizures, up to, and probably including part of the FMR2 gene. Other variant phenotypes were associated with deletions extending distal from the IDS gene and spanning some or all of the genes we have identified in this region.
Patients with rearrangements
To identify the novel 3' sequences observed in the IDS transcript from MPS-II patients with a rearrangement between IDS and IDS\|/, we carried out RT-PCR using primers in IDS and gene X (Fig. 3) . Three products were isolated and sequenced (GenBank accession nos U66053, U66054 and U66055). The larger product contained exons from IDS, X and a previously unidentified exon located near the 5' end of gene W, but from the complementary strand. The smaller product contained only IDS and gene X exons. Transcripts containing this novel exon have also been detected in normal individuals where it is expressed from the other duplicated site as part of gene Z' (data not shown). The presence of this novel transcript raised the possibility that the mutation in these patients may have affected expression of normal gene X and gene W transcripts.
To test these possibilities RT-PCR and LA-PCR (20) based approaches were designed using primers and probes to differentiate between the related genes. The IDS transcripts found in the rearrangement patients do not include gene X exon 1. LA-PCR was carried out to amplify gene X transcripts (Fig. 4a ) and then Southern analysis was performed using a gene X exon 1 specific probe (Fig. 4b) . A hybridising band of the correct size was detected in all the patients examined indicating that in addition to the fusion transcript, normal expression of gene X transcripts also occurred (results from a single individual are shown in Fig. 4b) .
It was also possible that the expression of gene W had been affected in patients with the rearrangement due to its proximity to IDSv|/. The 3' exon of gene W is located immediately adjacent to the intron 7 homologue in the pseudogene, and therefore within, at most, a few hundred base pairs of the recombination site in these patients (K. Lagerstedt, etal. in preparation). If expression of normal transcripts from these genes is disrupted in the rearrangement patients, then it is unlikely that they could be candidate genes for any of the variant phenotypes seen in the deletion patients.
In normal individuals gene W is only partially duplicated. Therefore, primers which amplify a fragment spanning from one of the duplicated exons to one of the unduplicated exons were used in RT-PCR reactions. Expression of this gene was found to be high in white blood cells and the HT1080 cell line relative to the available patient and control fibroblasts. A nested PCR approach was therefore used to illustrate that low level expression of this gene is present in fibroblasts from both normal individuals and all of the patients examined (Fig. 5) .
These results indicate that expression of both genes W and X does not appear to be significantly disrupted by the recombination event which has occurred in these individuals. These patients all have severe MPS-II with phenotypes which are consistent with this disorder. For this reason, both genes could be considered candidates for the variant phenotypes which correlate with deletions extending distal of the IDS locus.
DISCUSSION
Large scale genomic sequencing from around the IDS locus has enabled us to carry out a comparison of the genotypes observed in patients suffering from variations of Hunter syndrome. STS markers from Xq28 and PCR primers from genes found within our sequence contigs were used to map the deletion breakpoints in four Hunter syndrome patients with large scale deletions spanning the IDS gene. All four individuals have symptoms which are considered atypical of Hunter syndrome, in addition to the severe form of the disorder. These atypical symptoms include ptosis, obstructive sleep apnoea, Hurler-like symptoms and seizures. In two of the patients the occurrence of seizures correlated with a deletion extending proximal of the IDS gene, towards, and probably including, part of the FMR2 locus. The phenotypes observed in other individuals (ptosis, Hurler-like symptoms) correlate with a larger distal deletion spanning the loci that we have identified in this region, including genes X and W. PCR was carried out on reverse transcribed total RNA using primers in IDS exon 5 (IDS8) and gene X exon 4 (R738), followed by a nested reaction using primers in IDS exon 6 (IDS 13) and gene X exon 3 (R720). Sequence of the cloned PCR products was obtained (GenBank accession nos U66053, U66054 and U66055). The larger product contained part of IDS exons 6 and 7, a novel exon located distal of gene W, and gene X exon 2 and part of exon 3. The smaller product lacked the novel exon. Exon 1 from gene X and the gene W exons are not spliced into this transcript.
In a second group of individuals the IDS locus is disrupted by homologous recombination with the neighbouring IDS pseudogene. IDS transcripts in these individuals contain exons from one other locus (X) and a novel exon located distal of gene W, in addition to IDS. These exons are normally found distal to the IDS gene in Xq28. RT-PCR based approaches were utilised to show that normal gene X and W transcripts are still expressed in all the patients examined, indicating that the recombination event has not disrupted normal expression of these two genes. The apparently normal functioning of these genes in a group of patients without any phenotypic variation, in addition to the close proximity of these loci to the IDS gene, indicates that they should be considered candidate genes for the unusual symptoms (ptosis, Hurler-like symptoms, but not seizures) associated with deletions extending distal of IDS in the deletion patients.
This homologous recombination event between the IDS gene and IDS\|/ is the most commonly observed mutation, accounting for ~ 13% of all cases of Hunter syndrome (10) . A mechanistically similar homologous recombination event results in-50% of cases of severe haemophilia A, where recombination occurs between the A gene located in exon 22 of the factor VIII gene and one of two A genes located -500 kb distal (21, 22 Template for LA-PCR was generated by making reverse transcribed total RNA primed with oligo (dTis), followed by ligation of an anchor oligonucleotide to the 3' end of the reaction products. Nested PCR reactions were carried out using a primer from gene X exon 3 (R720) and a primer from the anchor (a), followed by primers from exon 2 (R741) and the anchor primer to amplify all gene X transcripts. PCR was also performed on the same templates with primers from gene X exon 2 (R741) and IDS exon 6 (IDS 13). This primer combination amplified only transcripts containing exons from both IDS and gene X. Southern hybridisation was performed on the reaction products using a oligonucleotide probe specific for gene X exon 1 (R838 syndrome and haemophilia A are characterised by heterogeneous phenotypes ranging from mild to severe, and in both disorders the most common cause of the severe form of the disease is homologous recombination between duplicated, or partially duplicated, genes. A second rearrangement between the IDS gene and IDS\|/ has recently been described (23) . In this patient interchromosomal recombination between the IDS gene and IDSvj/ is thought to have occurred during meiosis, resulting in two copies of the pseudogene on one chromosome and the loss of -1. genomic material are responsible for instability resulting in a large proportion of Hunter syndrome cases (10) . Expansion of the triplet repeat element at the FRAXE locus results in mild mental retardation in the affected individuals (15) (16) (17) . There have been no reports of the occurrence of seizures associated with this disorder, and it is difficult to predict how the loss of both the IDS locus and part of the FMR2 gene should manifest at the phenotypic level. It is thought that the distance between IDS and the FRAXE triplet repeat is -750 kb (19) . However, the FMR2 gene is very large and thought to span as much as 650 kb (18, 19) . It remains possible that there are unidentified loci located between our IDS sequence contig and the 3' end of the FMR2 gene.
In summary, analysis of mutations in patients with severe Hunter syndrome, with and without variant phenotypes, has identified a number of candidate genes for the observed atypical symptoms. Continued analysis of this region, and of additional MPS-II deletion patients, will be important for further elucidation of the genetic differences between subtle variants of Hunter syndrome.
MATERIALS AND METHODS
Cosmids
All cosmids were derived from the human X chromosome flow-sorted library prepared at Lawrence Livermore National Laboratory (LLNL). The cosmids characterised in this study are identified using the LLNL nomenclature (e.g., U112G10); this name can be used to identify the original clones from the LLNL X-chromosome cosmid library. Cosmid DNA was isolated and purified using Qiagen Plasmid Maxi Kit columns and then further purified by caesium chloride banding. Cosmid walks to isolate minimally overlapping cosmids were performed as described previously (24) .
Sequencing
M13 shotgun libraries were prepared from physically sheared cosmid DNA using one of two adapter-based strategies (25, 26) . Sequence template was prepared and sequenced as described (27, 28) . Reverse sequencing template was prepared using a modified asymmetric PCR protocol (29) . Dye primer sequencing using sequence-specific primers and Ml3 templates was performed for gap closure. Reagent kits were provided by Applied Biosystems and reactions were performed on PEC 9600 thermocyclers. Sequence reactions were electrophoresed on ABI 373 or 377 DNA sequencers.
Sequence assembly
Sequence reads were edited using the software SEQPREP developed by the Molecular Biology Computational Resource Centre at Baylor College of Medicine. After editing sequence was assembled using the Staden XDAP and XGAP software (30) . Gap closure was performed as described previously (29, 31) , and by utilising an M13 nested deletion protocol for gaps where there were no available clones in the shotgun sequencing library. Clones which spanned these gaps were selected and then a nested deletion protocol carried out as described previously (32) .
Computer analysis programs
Computer analysis of sequence was via a suite of programs assembled by the Baylor College of Medicine genome informatics group. They include BLAST (33) 
Hybridisations
Standard procedures for Southern hybridisation were utilised (38) , except that transfers were carried out using alkaline conditions. In addition, hybridisation buffer contained 1 M NaHPO4 (pH 7.0) and 7% SDS, and wash buffer contained 0.08-0.2 M NaHPO 4 (pH 7.0) and 1% SDS. Probes were generated using Rediprime kits supplied by Amersham, and purified using NICK columns from Pharmacia. Oligodeoxynucleotide probes were labelled using calf alkaline phosphatase as described previously (38) . The labelled oligodeoxynucleotide was purified using NICK (>20mer) or NAP-25 (<20mer) columns from Pharmacia. 
RT-PCR, LA-PCR and 3'-RACE
Total RNA was isolated from human fibroblasts, HT1080 human fibrosarcoma cells or white blood cells using guanidinium thiocyanate extraction and caesium chloride centrifugation as described previously (38) . Single-strand DNA was synthesised using oligo (dT 15 ) for use in RT-PCR or modified LA-PCR (20) reactions. For 3'-RACE (39), oligo (dTis) containing a universal tail was used. In some cases a nested PCR approach was used when performing LA-PCR or 3'-RACE. Primers used in RT-PCR, LA-PCR and 3'-RACE are shown in Table 1 .
PCR
PCR was performed using AmpliTaq or AmpliTaq Gold DNA polymerase in a PEC 4800 thermocycler. Each 50 (il reaction contained 1.5 mM MgCl 2 ,50 mM KC1,10 mM Tris-HCl pH 8.3, 25 mM each dNTP, 20 pmol each primer and 2.5 U AmpliTaq. DMSO (10% vol/vol) was included in reactions where template DNA had high GC content. For template, -10 ng of cosmid DNA, 100 ng of genomic DNA or 2 |j.l of reverse transcriptase reaction was used. PCR conditions were 94°C/3 min, followed by 30 reaction cycles of 94°C/30 s, 55°C/30 s, 68°C/2 min. After completion of the cycle, samples were held at 68°C/7 min and then cooled to 4°C. Primers used in PCRs are shown in Table 1 .
Screening cDNA libraries
Library plating and screening was carried out as described previously (38) . Rediprime kits (Amersham) were used to label the probes, which were purified using Pharmacia NICK columns. Single positive plaques were identified after tertiary screening and phagemid was isolated using standard procedures (38) .
Sequencing of ESTs, isolated cDNAs, PCR, RT-PCR, LA-PCR, and 3-RACE products
Products from RT-PCR, LA-PCR, 3'-RACE and PCR were cloned into pGEM-T vector supplied by Promega. Dye-primer universal and reverse sequence reads were performed on each clone. Complete sequence was obtained using sequence specific primers and dye-terminator chemistry. For cDNAs >1.5 kb in length a concatenated cDNA library construction procedure was used to generate an Ml3 shotgun library of the original cDNAs (40) . Shotgun sequencing using dye-primer chemistry was used to sequence these clones.
Sequence
